Material matter: European phase 3 Part 1 approval lapses for CTP13 SC, subcutaneous Remsima, in paediatric Crohn disease after a development strategy change
DART
Celltrion, Inc.
Filed Jun 18, 2026 KST · Filing
· receipt 20260618800908
kstock has not written this one up.
The title above is a translation of the Korean form name; the filing itself is on DART, in
Korean.
Read the original on DART ↗Korean. DART is Korea's electronic disclosure system, run by the Financial Supervisory
Service — the filing equivalent of EDGAR.
Korean form name: 투자판단관련주요경영사항 (개발 전략 변경에 따른 CTP13 SC(램시마 피하주사 제형) 유럽 임상 3상 시험 계획 Part 1 승인 만료 (크론병 소아 환자))